TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Following a September 2026 restructuring that paused its hematologic malignancies program in favor of its in vivo TCR-T work in solid tumors, the sell-side view shifted sharply. H.C. Wainwright analyst Andres Maldonado downgraded the stock to Neutral from Buy and cut the target to $1 from $7, saying the restructuring "raises more questions than answers" about whether the company's cash runway can support its promised 2027 milestones. Around the same time, Wedbush cut its target to $1 from $5 and moved to Hold, while LifeSci Capital also downgraded to Hold.
Several data providers now report an average 12-month analyst target of $1.00, with the consensus rating at Hold. Because the recent revisions pulled targets down from a prior range of roughly $5 to $7, the current target range is narrow, clustering around $1.00. This is the arithmetic mean of the verified, current analyst targets, not a prediction that the stock will reach that level. The wide downward revision between 2025 and 2026 illustrates how quickly biotech price targets can change when clinical priorities and balance sheets shift.
The stock has traded around $0.19 in early November 2026, down more than 90% over the past year and sitting near the bottom of a 52-week range of roughly $0.17 to $1.47. At that price, moving to the $1.00 target would require a gain of approximately 426%, a very large move by any standard. Reaching the target would likely require both the successful execution of the in vivo TCR-T strategy and a meaningful improvement in investor confidence around funding and Nasdaq listing compliance. The path is not linear: it would depend on clinical data, financing, and a stabilization of the share price above the $1.00 minimum bid threshold the company currently falls short of.
The company's narrowed focus on its in vivo TCR-T platform for solid tumors could, over time, sharpen the investment story and reduce cash burn relative to the prior multi-program approach. Positive early clinical data, new partnerships, or successful fundraising would address the two most pressing investor concerns: pipeline validity and balance-sheet durability. A completed reverse stock split, which shareholders will consider at a November 20, 2026 special meeting, could also lift the nominal share price back above $1.00 and restore Nasdaq compliance, removing a near-term overhang. Because the stock is highly volatile, even modest positive catalysts have historically produced outsized percentage moves in either direction.
The principal risks are financing and solvency. The company has disclosed a going-concern warning and received a Nasdaq deficiency notice in August 2026 after trading below $1.00 for 30 consecutive days; it has until February 2027 to regain compliance. A reverse split may cure the listing problem but does not address the underlying cash runway, and the departure of senior executives, including the CFO and CMO, adds execution uncertainty. Dilutive financing, disappointing clinical results, or failure to secure capital could push the shares lower and make the $1.00 target, already a very large percentage move away, harder to justify.
The $0.17–$0.18 area represents the recent 52-week low and is the most durable nearby support zone, while the $1.00 level serves both as a psychological round number and as the Nasdaq minimum-bid compliance threshold. Above that, prior highs near $1.47 mark the next significant resistance. The stock's long-term trend remains firmly negative, and any move toward $1.00 would first require the price to hold above the low and then clear multiple overhead levels created by the extended decline.
Analyst price targets for TCRX generally reflect a roughly 12-month research horizon, though the company has not published a formal horizon for the current $1.00 targets. Investors should watch the November 2026 special meeting on the reverse split, any financing or partnership announcements, updates on the in vivo TCR-T program, and quarterly cash position disclosures. Nasdaq compliance progress ahead of the February 2027 deadline, along with any analyst target or rating revisions, will be especially relevant to whether the $1.00 objective remains credible.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile name like TCRX, these signals can help traders surface opportunities, keep tabs on shifting momentum, and spot emerging trends more efficiently than manual screening alone. Traders interested in a data-driven complement to fundamental research can explore these signals to monitor positions and identify changing conditions across the market.
The $1.00 target for TScan Therapeutics reflects the arithmetic mean of current analyst price targets that were sharply reduced after the September 2026 restructuring. From a price near $0.19, reaching that level would require an increase of about 426%, an exceptionally large move that hinges more on financing, Nasdaq compliance, and early-stage pipeline execution than on near-term fundamentals. Supporters point to a simplified strategic focus and potential clinical catalysts, while skeptics emphasize the going-concern warning, cash runway doubts, and delisting risk. There is no guarantee the stock will approach the target, and the wide gap between the current price and the target underscores both the upside that analysts' figures imply and the substantial uncertainty embedded in a clinical-stage biotech trading near its lows.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with CELC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then CELC could also see price increases.
| Ticker / NAME | Correlation To TCRX | 1D Price Change % | ||
|---|---|---|---|---|
| TCRX | 100% | +0.22% | ||
| CELC - TCRX | 36% Loosely correlated | -4.07% | ||
| MGX - TCRX | 34% Loosely correlated | +8.04% | ||
| AGIO - TCRX | 33% Poorly correlated | +3.34% | ||
| ANIX - TCRX | 32% Poorly correlated | -9.15% | ||
| MLTX - TCRX | 32% Poorly correlated | +7.56% | ||
More | ||||